• ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE and now dual listed on Euronext Growth Brussels

Significant highlights

Developing innovative drugs

ImmuPharma PLC is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of our peers.

We have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS).  ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates

We have a partnership-based business model, a small core of full time staff, a low R&D cost base, a strong balance sheet and diversified compounds and pipeline.

ImmuPharma has had loyal and supportive shareholders since its listing on AIM that have supported the Company through its history and has helped finance product development.

Share Price

Market Cap

Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited

Joint Broker
Stanford Capital Partners Limited

Joint Broker
Si Capital Limited

Public Relations & Investor Relations

4Reliance (Euronext Growth Listing Sponsor)

Degroof Petercam (Euronext Liquidity Provider)

Professional advisers

Nexia Smith & Williamson Audit Limited
London, U.K.

Legal Representatives
Bircham Dyson Bell LLP
London, U.K.

Badertscher Rechtsanwälte AG
Zurich, Switzerland

Company Secretary
Orana Corporate LLP

Patent Agents
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France

Under contract with a leading manufacturer in the peptides field

“We are now on a new page in ImmuPharma’s future, following on from the signing of our recent licensing and development agreement with Avion Pharmaceuticals, who are now funding an international Phase III trial for our lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and we look forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US”

Dimitri Dimitriou, CEO of ImmuPharma PLC

December 2020

To contact us click here